A Phase 1, Randomised, Open-label, 4-Period Crossover Study to Develop an In Vitro-In Vivo Correlation for Olaparib Tablets in Subjects With Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 17 Jan 2019
At a glance
- Drugs Olaparib (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Acronyms IVIVC
- Sponsors AstraZeneca
- 09 Jan 2019 Planned End Date changed from 24 Dec 2018 to 17 Jun 2019.
- 09 Jan 2019 Planned primary completion date changed from 24 Dec 2018 to 17 Jun 2019.
- 15 Jun 2018 New trial record